Metagenomi Therapeutics Inc (MGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -23,059 | -87,868 | -65,340 | -44,947 | -25,039 |
| Depreciation Amortization | 915 | 2,105 | 1,275 | 781 | 274 |
| Accounts receivable | 305 | 952 | 297 | 384 | 245 |
| Accounts payable and accrued liabilities | 795 | 1,054 | 708 | 2,284 | 2,210 |
| Other Working Capital | -2,918 | -22,094 | -15,849 | -10,213 | -2,278 |
| Other Operating Activity | 2,787 | 16,959 | 13,563 | 7,618 | 1,746 |
| Operating Cash Flow | $-21,175 | $-88,892 | $-65,346 | $-44,093 | $-22,842 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -25 | -537 | -452 | -378 | -288 |
| Purchase Of Investment | -36,748 | -66,408 | -46,859 | -40,796 | -22,287 |
| Sale Of Investment | 40,759 | 170,474 | 118,474 | 84,974 | 47,303 |
| Investing Cash Flow | $3,986 | $103,529 | $71,163 | $43,800 | $24,728 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 202 | 109 | 109 | N/A |
| Other Financing Activity | -27 | -558 | -539 | -352 | -77 |
| Financing Cash Flow | $-27 | $-356 | $-430 | $-243 | $-77 |
| Beginning Cash Position | 46,915 | 32,634 | 32,634 | 32,634 | 32,634 |
| End Cash Position | 29,699 | 46,915 | 38,021 | 32,098 | 34,443 |
| Net Cash Flow | $-17,216 | $14,281 | $5,387 | $-536 | $1,809 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,175 | -88,892 | -65,346 | -44,093 | -22,842 |
| Capital Expenditure | -25 | -574 | -489 | -415 | -288 |
| Free Cash Flow | -21,200 | -89,466 | -65,835 | -44,508 | -23,130 |